Morgan Stanley’s Oric Pharmaceuticals ORIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.01M | Buy |
394,785
+226,114
| +134% | +$2.3M | ﹤0.01% | 4235 |
|
|
2025
Q1 | $941K | Sell |
168,671
-178,684
| -51% | -$997K | ﹤0.01% | 5027 |
|
|
2024
Q4 | $2.8M | Sell |
347,355
-24,372
| -7% | -$197K | ﹤0.01% | 4451 |
|
|
2024
Q3 | $3.81M | Sell |
371,727
-52,195
| -12% | -$535K | ﹤0.01% | 4173 |
|
|
2024
Q2 | $3M | Buy |
423,922
+123,099
| +41% | +$870K | ﹤0.01% | 4290 |
|
|
2024
Q1 | $4.14M | Sell |
300,823
-659,839
| -69% | -$9.07M | ﹤0.01% | 4060 |
|
|
2023
Q4 | $8.84M | Buy |
960,662
+836,471
| +674% | +$7.7M | ﹤0.01% | 4015 |
|
|
2023
Q3 | $751K | Sell |
124,191
-24,390
| -16% | -$148K | ﹤0.01% | 4959 |
|
|
2023
Q2 | $1.15M | Buy |
148,581
+54,552
| +58% | +$423K | ﹤0.01% | 4752 |
|
|
2023
Q1 | $536K | Buy |
94,029
+36,454
| +63% | +$208K | ﹤0.01% | 5212 |
|
|
2022
Q4 | $339K | Buy |
57,575
+19,885
| +53% | +$117K | ﹤0.01% | 5432 |
|
|
2022
Q3 | $121K | Sell |
37,690
-41,513
| -52% | -$133K | ﹤0.01% | 5984 |
|
|
2022
Q2 | $354K | Buy |
79,203
+6,006
| +8% | +$26.8K | ﹤0.01% | 5593 |
|
|
2022
Q1 | $391K | Buy |
73,197
+26,830
| +58% | +$143K | ﹤0.01% | 5553 |
|
|
2021
Q4 | $681K | Buy |
46,367
+27,453
| +145% | +$403K | ﹤0.01% | 5358 |
|
|
2021
Q3 | $396K | Sell |
18,914
-127,101
| -87% | -$2.66M | ﹤0.01% | 5634 |
|
|
2021
Q2 | $2.58M | Buy |
146,015
+133,130
| +1,033% | +$2.35M | ﹤0.01% | 4439 |
|
|
2021
Q1 | $316K | Sell |
12,885
-18,324
| -59% | -$449K | ﹤0.01% | 5394 |
|
|
2020
Q4 | $1.06M | Buy |
31,209
+30,270
| +3,224% | +$1.02M | ﹤0.01% | 4634 |
|
|
2020
Q3 | $23K | Sell |
939
-1,914
| -67% | -$46.9K | ﹤0.01% | 6009 |
|
|
2020
Q2 | $96K | Buy |
+2,853
| New | +$96K | ﹤0.01% | 5420 |
|